The Telix (ASX:TLX) share price is wobbling today

The Telix (ASX: TLX) share price is up and down today after news of the company’s successful kidney cancer imaging trial.
The post The Telix (ASX:TLX) share price is wobbling today appeared first on The Motley Fool Australia. –

A doctor looks unsure, indicating share price uncertainty for ASX medical companies

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has the wobbles today after the company shared news of a successful trial.  

The biopharmaceutical company announced that its kidney cancer imaging product’s Japanese clinical study met all objectives for its first phase.

The Telix share price plummeted from its opening price of $3.96 to an intraday low of $3.87, before gaining – and losing – ground through the morning trade. At the time of writing, Telix shares are down 0.51%, trading at $3.89.

Let’s take a closer look at the news driving the Telix share price today.

Successful study

Today, Telix shared news that its clinical study, Zirconium Dosing and Comparison in Japan (ZIRDAC-JP), has proven successful. The study met its objectives of positively measuring the safety, tolerability, required radiation dosage, and movement within the body of its TLX250-CDx.

TLX250-CDx is an imaging radiopharmaceutical for the imaging of clear cell renal cell carcinoma (ccRCC), the most aggressive form of kidney cancer. ccRCC makes up 70% to 85% of all kidney cancers. According to Telix, TLX250-CDx targets a cell-surface antigen called Carbonic Anhydrase IX.

The company states that many patients are diagnosed with a renal mass, and TLX250-CDx is able to determine whether they are cancerous in a non-invasive inspection.

Phase 1 of the study was completed at Yokohama City University Hospital. There, six patients with an unspecified renal mass underwent dosing with TLX250-CDx, followed by positron emission tomography imaging.

All 6 patients completed the study with no adverse events. The whole-body and organ-specific radiation dosage needed for TLX250-CDx showed no difference between Japanese and Caucasian patients.

Commentary from management

Telix chief medical officer Dr Colin Hayward said the company was encouraged by the study’s results:

We now plan to consult with the Japanese regulator to confirm the design of the next stage of development for TLX250-CDx, with the objective of bridging to Telix’s international Phase III ZIRCON study, currently enrolling patients at 36 sites globally.

Telix pharmaceuticals share price snapshot 

If investors embrace today’s news, the Telix share price may break into the ASX 2021 green.

Currrently, the Telix share price is down 2.9% year to date, although it’s up a whopping 238% over the last 12 months.

The company has a market capitalisation of around $1 billion, with approximately 281 million shares outstanding.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The Telix (ASX:TLX) share price is wobbling today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!